Short-term benefit of neoadjuvant hormone therapy in patients with localized high-risk or limited progressive prostate cancer

MLA

Ma BL, et al. “Short-Term Benefit of Neoadjuvant Hormone Therapy in Patients with Localized High-Risk or Limited Progressive Prostate Cancer.” Cancer Management and Research, vol. ume 11, May 2019, pp. 4143–51. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.51d5935bc89247f9b4929b805ac8c060&authtype=sso&custid=ns315887.

APA

Ma BL, Yao L, Fan Y, Wang Y, Meng YS, Zhang Q, He ZS, Jin J, & Zhou LQ. (2019). Short-term benefit of neoadjuvant hormone therapy in patients with localized high-risk or limited progressive prostate cancer. Cancer Management and Research, ume 11, 4143–4151.

Chicago

Ma BL, Yao L, Fan Y, Wang Y, Meng YS, Zhang Q, He ZS, Jin J, and Zhou LQ. 2019. “Short-Term Benefit of Neoadjuvant Hormone Therapy in Patients with Localized High-Risk or Limited Progressive Prostate Cancer.” Cancer Management and Research ume 11 (May): 4143–51. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.51d5935bc89247f9b4929b805ac8c060&authtype=sso&custid=ns315887.